Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study
Sep 2026· Breast Cancer· Vol 18· 0 citations· 41 references
Medicine
TL;DR
In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.
Abstract
Background Neoadjuvant pembrolizumab-based chemoimmunotherapy is standard of care for early-stage triple-negative breast cancer (TNBC). Real-world data remain limited outside trial populations, particularly in the Middle East, and hormone receptor (HR)-low tumors (ER/PR 1–10%) are undercharacterised in this setting. Methods We conducted a retrospective cohort study of 149 patients with non-metastatic TNBC or HR-low breast cancer at King Hussein Cancer Center, Jordan (April 2021–September 2024). Primary endpoint was pCR (ypT0/Tis ypN0), analysed across all 149 treatment-initiated patients with the 7 who did not undergo surgery classified as non-pCR; Firth penalised logistic regression identified factors independently associated with pCR. Safety was assessed in all 149. Results The overall pCR rate was 59.1% (88/149). On Firth penalised multivariable logistic regression, three variables were independently associated with pCR: grade 3 histology (aOR 4.44, 95% CI 1.61–13.66, p = 0.004), pathogenic germline mutation (aOR 3.19, 95% CI 1.26–9.11, p = 0.014), and age younger than 40 years (aOR 2.82, 95% CI 1.20–7.10, p = 0.017). HR-low tumors (n = 15) achieved 66.7% pCR, comparable to HR-negative disease (58.2%). Immune-related adverse events occurred in 44 patients (29.5% of 149); grade ≥3 events in 9 (20.5% of irAE patients; 6.0% of the cohort); permanent immunotherapy discontinuation for treatment-limiting toxicity in 6 (13.6% of irAE patients; 4.0% of the cohort). Hospitalization occurred in 33.6%, predominantly due to febrile neutropenia. At a median follow-up of 27.3 months, 137 of 149 patients (91.9%) were alive and 136 (91.3%) were recurrence-free; all 13 recurrences were distant. Among surgical patients, disease-free survival was 96.6% in the pCR group versus 85.2% with residual disease (log-rank p = 0.011). Conclusion In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data. Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR; the HR-low findings are exploratory. These results support prospective biomarker-driven trials in early TNBC across underrepresented populations.
AIMS
To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications.
METHODS AND RESULTS
A total of 203 patients with TNBC treated...
Jiwon Koh, K. J. Suh, H. Park et al.· Histopathology· 0 citations
Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER− and one-third with HER2+/ER+ breast cancer, and these findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.
N. Tung, Feng-Min Zhao, A. DeMichele et al.· Journal of Clinical Oncology· 2 citations
Germline BRCA1/2 pathogenic variants (gBRCA-PV) are associated with chemosensitivity in triple-negative breast cancer (TNBC), but whether higher pathologic complete response (pCR) rates translate into improved long-term outcomes remains uncertain. We assessed associations of gBRCA-PV status with pCR, recurrence-free su...
Paulina Gebhart, F. Heinzl, C. Kahl et al.· Breast Cancer· 0 citations
Background Pembrolizumab has become standard neoadjuvant systemic therapy (NST) for early estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-normal early breast cancer (eBC). Electronic health record (EHR) data may support real-world assessment of its implementation in routine care. Patien...
A. Henriksen, A. Lundgren, M. Andersen et al.· ESMO real world data and dig...· 0 citations
Triple‑negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of immunotherapy, the optimal neoadjuvant chemotherapy backbone remains poorly defined. We examined real-world treatment patterns and response rates among patients receiving a carboplatin-based regimen, with...
Matthew R. Kroll, Mary C. Schroeder, J. M. Neuner et al.· Breast Cancer Research and T...· 0 citations
The findings support the feasibility of integrating both neoadjuvant treatment strategies into routine surgical practice; however, confirmation in larger prospective studies is warranted.
K. Wimmer, Katharina Kantner, R. Exner et al.· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.